GlassScriptPhysician profile
Aziz A Ashirov
NPI 1295128783
$2,999.27
in general payments reported to CMS, 2019-2025
13 companies · $947 in 2025
The $947 reported for 2025 was more than what 99% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
See the full distribution for Nurse Anesthetist, Certified Registered
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.66 · 2022: $219 · 2023: $1,032 · 2024: $789 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $776.77 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $641.97 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $345.76 | 2023-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $298.67 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $234.86 | 2022-2025 | Ocaliva |
| Jabil INC. | $200.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $155.82 | 2023-2025 | Dupixent |
| Genzyme Corporation | $124.90 | 2023 | |
| Madrigal Pharmaceuticals | $86.73 | 2025 | Rezdiffra |
| Celgene Corporation | $67.36 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $34.77 | 2023 | Sutab |
| C. R. Bard, INC. & Subsidiaries | $19.00 | 2024 | |
| Nevro Corp. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aziz Ashirov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.